The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and semiconductors. The investigations are being conducted under Section 232 of the Trade Expansion Act of 1962, which authorizes the President to impose tariffs or other trade restrictions if an investigation determines that importation of particular goods affect national security. Those goods have received exemptions from tariffs on imported goods that began April 5. The agency will accept comments on domestic production, the role of foreign supply chains, the impacts of trade policy and other information related to pharmaceutical and semiconductor imports for 21 days following publication in the April 16 Federal Register. 

Headline
The AHA commented today on the Centers for Medicare & Medicaid Services’ proposed rule on the Global Benchmark for Efficient Drug Pricing Model, or…
Headline
The Administration for Strategic Preparedness and Response Feb. 18 announced an investment that will focus on resolving a frequent shortage of oseltamivir,…
Headline
The House Energy and Commerce Subcommittee on Health Feb. 11 hosted a hearing titled “Lowering Health Care Costs for All Americans: An Examination of the…
Headline
The White House yesterday launched TrumpRx, the direct-to-consumer platform that will serve as a hub to direct cash-paying consumers to drug manufacturers…
Headline
The Department of Labor has issued a proposed rule to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to disclose…
Headline
The Department of Health and Human Services Office of Inspector General Jan. 27 released a bulletin addressing how direct-to-consumer drug programs can sell…